HBV感染“新型”生物标志物的“前世今生”

唐红

doi:10.3969/j.issn.1001-5256.2019.10.001

HBV感染“新型”生物标志物的“前世今生”

DOI: 10.3969/j.issn.1001-5256.2019.10.001

唐红

四川大学华西医院感染性疾病中心

详细信息

中图分类号: R512.62
计量
- 文章访问数: 1521
- HTML全文浏览量: 41
- PDF下载量: 585
- 被引次数: 0
出版历程
- 收稿日期: 2019-09-10
- 出版日期: 2019-10-20

The development history of new biomarkers for hepatitis B virus infection

Tang Hong

Center of Infectious Diseases,West China Hospital of Sichuan University

摘要

摘要: 慢性乙型肝炎抗病毒治疗的目标是最大限度的长期抑制HBV复制,减轻肝细胞炎症及肝纤维化,延缓和减少肝衰竭、肝硬化失代偿、肝细胞癌及其他并发症的发生。目前可能用于临床抗病毒疗效评价的生物学标志物除了应用时间较长的血清HBV DNA外,近年来肝细胞内的HBV cccDNA、血清乙型肝炎核心相关抗原定量、血清HBV RNA定量、血清HBsAg定量和血清抗-HBc定量等"新型"生物标志物的临床价值也逐步得到广泛关注,特别是在监测与评价抗病毒疗效、预测停药后病毒反弹风险以及预测肝癌发生风险等方面具有重要的临床意义。
- 乙型肝炎病毒 /
- 生物标记 /
- 治疗学
Abstract: The objective of antiviral therapy for chronic hepatitis B is to maximize the long-term inhibition of hepatitis B virus(HBV) replication,reduce hepatocyte inflammation and liver fibrosis,and delay and reduce liver failure,decompensated cirrhosis,hepatocellular carcinoma,and other complications. In addition to serum HBV DNA which has been used for a long time,new biomarkers such as intrahepatic HBV cccDNA,serum HBcrAg,serum HBV RNA,serum HBsAg,and serum anti-HBc are commonly used in recent years to evaluate antiviral response in clinical practice,and their clinical value has attracted more and more attention. Such biomarkers have important clinical significance in monitoring and evaluating antiviral response and predicting the risk of viral rebound after drug withdrawal and the risk of hepatocellular carcinoma.
- hepatitis B virus /
- biomarkers /
- therapeutics

HTML全文

参考文献(12)

[1] ZHONG Y,HAN J,ZOU Z,et al. Quantitation of HBV covalently closed circular DNA in micro formalin fixed paraffin-embedded liver tissue using rolling circle amplification in combination with real-time PCR[J]. Clin Chim Acta,2011,412(21-22):1905-1911.

[2] ZHONG Y,HU S,XU C,et al. A novel method for detection of HBVcccDNA in hepatocytes using rolling circle amplification combined with in situ PCR[J]. BMC Infect Dis,2014,14:608.

[3] WANG J,SHEN T,HUANG X,et al. Serum hepatitis B virus RNA is encapsidated pregenome RNA that may be associated with persistence of viral infection and rebound[J]. J Hepatol,2016,65(4):700-710.

[4] WANG J,SHENG Q,DING Y,et al. HBV RNA virion-like particles produced under nucleos(t)ide analogues treatment are mainly replication-deficient[J]. J Hepatol,2018,68(4):847-849.

[5] CORNBERG M,WONG VW,LOCARNINI S,et al. The role of quantitative hepatitis B surface antigen revisited[J]. J Hepatol,2017,66(2):398-411.

[6] CHEN J,ZHANG DH,XU CR,et al. Quantitative hepatitis B surface antigen combined with hepatitis B e antigen as sustained virological response predictors during extended therapy with Peginterferon alfa-2a for hepatitis B e antigen-positive chronic hepatitis B[J]. J Clin Virol,2015,72:88-94.

[7] YU DM,LI XH,MOM V,et al. N-glycosylation mutations within hepatitis B virus surface major hydrophilic region contribute mostly to immune escape[J]. J Hepatol,2014,60(3):515-522.

[8] SONG LW,LIU PG,LIU CJ,et al. Quantitative hepatitis B core antibody levels in the natural history of hepatitis B virus infection[J]. Clin Microbiol Infect,2015,21(2):197-203.

[9] FAN R,SUN J,YUAN Q,et al. Baseline quantitative hepatitis B core antibody titre alone strongly predicts HBe Ag seroconversion across chronic hepatitis B patients treated with peginterferon or nucleos(t)ide analogues[J]. Gut,2016,65(2):313-320.

[10] MAK LY,WONG DK,CHEUNG KS,et al. Review article:Hepatitis B core-related antigen(HBcrAg):An emerging marker for chronic hepatitis B virus infection[J]. Aliment Pharmacol Ther,2018,47(1):43-54.

[11] CHEN EQ,FENG S,WANG ML,et al. Serum hepatitis B core-related antigen is a satisfactory surrogate marker of intrahepatic covalently closed circular DNA in chronic hepatitis B[J].Sci Rep,2017,7(1):173.

[12] CHEN EQ,WANG ML,TAO YC,et al. Serum HBcrAg is better than HBV RNA and HBs Ag in reflecting intrahepatic covalently closed circular DNA[J]. J Viral Hepat,2019,26(5):586-595.

施引文献

资源附件(0)

访问统计